Share

September 2021; 8 (5) EditorialOpen Access

Combined Neurofilament Light and Optical Coherence Tomography Better Predicts Multiple Sclerosis Disease Activity Than Either Measure Alone

Julia Krämer, Heinz Wiendl, Sven G. Meuth, Philipp Albrecht
First published August 4, 2021, DOI: https://doi.org/10.1212/NXI.0000000000001054
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
371

Share

Article Information

vol. 8 no. 5 e1054
DOI: 
https://doi.org/10.1212/NXI.0000000000001054
PubMed: 
34348970
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • First Published August 4, 2021.
Copyright & Usage: 
Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Author Disclosures

    1. Julia Krämer, MD,
    2. Heinz Wiendl, MD (heinz.wiendl@ukmuenster.de),
    3. Sven G. Meuth, MD, PhD (sven.meuth@uni-duesseldorf.de) and
    4. Philipp Albrecht, MD (phil.albrecht@gmail.com)
  1. Julia Krämer, MD,
    2. Scientific Advisory Boards:

    1. None

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. None

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. None

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Heinz Wiendl, MD (heinz.wiendl@ukmuenster.de),
    3. Scientific Advisory Boards:

    1. (1) Biogen (2) Evgen (3) Genzyme (4) MedDay Pharmaceuticals (5) Merck Serono (5) Novartis (6) Roche Pharma AG (7) Sanofi-Aventis (8) UCB

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Alexion (2) Biogen (3) Cognomed (4) F. Hoffmann-La Roche Ltd. (5) Gemeinnützige Hertie-Stiftung (6) Merck Serono (7) Novartis (8) Roche Pharma AG (9) Sanofi-Genzyme (10) TEVA (11) WebMD Global

    Editorial Boards:

    1. (1) PLOS ONE, Editorial board member, since 2013 (2) Neurotherapeutics, since 2013 (3) Recent Patents on Inflammation & Allergy Drug Discovery

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1) Abbvie (2) Actelion (3) Argenx (4) Biogen (5) EMD (3) IGES (4) Johnson & Johnson (5) Merck (6) Novartis (7) Roche (8) Sanofi-Genzyme (9) Swiss Multiple Sclerosis Society (10)UCB

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Biogen (2) GlaxoSmithKline GmbH (3) Roche Pharma AG (4) Sanofi-Genzyme

    Research Support, Government Entities:

    1. (1) German Ministry for Education and Research (BMBF), 01GI1601E, principal investigator, 2016-2019 (2)Interdisciplinary Centre of Clinical Research (IZKF) Muenster, principal investigator, 2015-2018 (4)PML Consortium, principal investigator, 2016-2018 (5) German Research Foundation, principal investigator,SFB 1009 TP A3 + SFB-TR CRC128 TP A09 + SFB TR CRC128 TP A10, TR CRC128 TP V, TR CRC128 TP Z02 2016- 2020

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) Else Kröner Fresenius Foundation (2) Fresenius Foundation (3) Hertie Foundation (4) RE Children’s Foundation

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Sven G. Meuth, MD, PhD (sven.meuth@uni-duesseldorf.de) and
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Sven G. Meuth received honoraria for lecturing and travel expenses for attending meetings from Almirall, Amicus Therapeutics Germany, Bayer Health Care, Biogen, Celgene, Diamed, Genzyme, MedDay Pharmaceuticals, Merck Serono, Novartis, Novo Nordisk, ONO Pharma, Roche, Sanofi- Aventis, Chugai Pharma, QuintilesIMS, and Teva.

    Editorial Boards:

    1. NONE

    Patents:

    1. Effectivity of specific FXII/FXIIa inhibitors, especially rHA-Infestin-4, in treating neuroinflammatory diseases (WO 2013/113774 A1 und EP 2 263 110 A1) Biomarkers for diagnosis and management of neuro- immunological diseases (WO 2016/028699 A2) NR2B selective …

  4. Philipp Albrecht, MD (phil.albrecht@gmail.com)
  1. From the Department of Neurology with Institute of Translational Neurology (J.K., H.W.), University Hospital Münster, Germany; and Department of Neurology (S.G.M., P.A.), University Hospital Düsseldorf, Germany.
  1. Correspondence
    Dr. Krämer julia.kraemer{at}ukmuenster.de or Prof. Albrecht phil.albrecht{at}gmail.com
View Full Text

Article usage

Article usage: August 2021 to April 2023

AbstractFullPdfSource
Aug 2021035272Highwire
Sep 2021031548Highwire
Oct 202137627Highwire
Nov 202104020Highwire
Dec 202102313Highwire
Jan 20220199Highwire
Feb 20220167Highwire
Mar 20220279Highwire
Apr 202202610Highwire
May 202201818Highwire
Jun 202202919Highwire
Jul 202202110Highwire
Aug 20220259Highwire
Sep 202202819Highwire
Oct 202203416Highwire
Nov 202203917Highwire
Dec 202201812Highwire
Jan 202302811Highwire
Feb 202302211Highwire
Mar 20230108Highwire
Apr 2023086Highwire

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

Alert Me

Recommended articles